The International Neuromodulation Society

The Fastest-Growing, Worldwide Multidisciplinary Body Devoted to Building Knowledge of Neuromodulation

The International Neuromodulation Society (INS) is a non-profit group of clinicians, scientists and engineers dedicated to the scientific development and awareness of neuromodulation – the alteration of nerve activity through targeted delivery of a stimulus, such as electrical stimulation or chemical agents, to specific neurological sites in the body. The San Francisco-based INS was formed in 1989 and educates and promotes the field through meetings, its peer-reviewed journal Neuromodulation: Technology at the Neural Interface, explanatory content, and chapter websites. The INS also provides information for patients and produces rolling news briefs about this rapidly evolving field.

The INS Peer-Reviewed Journal – 8 Issues a Year

The INS journal Neuromodulation: Technology at the Neural Interface has a growing Impact Factor and is indexed in Index Medicus, MEDLINE and Pubmed from its first issue in 1998. Members may log in to the members-only section to read the journal online.

journal cover

+Submit a Manuscript.+

What is Neuromodulation?

Medical Professionals can learn about various considerations concerning neuromodulation and clinic contacts. Once your preliminary questions have been answered, please use the Contact Us facility to find out more and to discuss specific objectives. Others may simply wish to join the INS and one of its related chapter societies, please use the Membership Application.

Clinical trials that involve a wide range of emerging neuromodulation approaches are listed on our Research page. Neuromodulation clinical trials address symptom control through nerve stimulation in such condition categories as:

If you are not a medical professional and you are searching for information about neuromodulation and how these types of treatment could benefit a specific condition such as treatment-resistant headache or other chronic pain syndromes, you may find the sections titled Therapies, About Neuromodulation or FAQs particularly helpful.

Members may log in and visit the members-only section’s Global Discussion Forum

Breaking News Share

Company Completes Enrollment for Pilot Study of Vagus Nerve Stimulation in Rheumatoid Arthritis

Oct. 16, 2018 - SetPoint Medical announced it has completed enrollment of 14 patients in a U.S. pilot study to evaluate the safety and tolerability of its vagus nerve stimulator for rheumatoid arthritis that has not improved through multiple different biologic therapies. (P&T Community)

U.S. Department of Defense Gives $1.3 Million Research Grant to Study Neurostimulation to Minimize Ischemic Damage after Traumatic Brain Injury

Oct. 16, 2018 - A researcher at the Feinstein Institute for Medical Research has received $1.3 million from the U.S. Department of Defense's "Foundational Research for Autonomous, Unmanned, and Robotics Development of Medical Technologies (FORwARD)" program for research into trigeminal nerve stimulation to increase cerebral blood flow and cerebrovasodilation to minimize "secondary injury" from ischemia and hypoxia following traumatic brain injury, as explained in a 2017 paper. (NewsDay)

Presentation: Improvements Seen After Dorsal Root Ganglion Stimulation

Oct. 15, 2018 - Data presented at the annual meeting of the American Society of Anesthesiologists regarding 67 patients with chronic back and leg pain noted clinical improvements after dorsal root ganglion stimulation. The patients were followed for up to 18 months. (Healio)

To see select neuromodulation news by category, as well as news about the INS in particular, please visit the Newsroom. To see archived news briefs dating back to January 2011, visit the News Archive.

Continue Reading News Briefs
Last Updated on Monday, December 12, 2016 10:01 AM